New combo vs standard for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has spread and cannot be removed with surgery.
- You have not had any previous cancer treatment for the metastatic disease.
- Your doctor has determined you cannot tolerate strong chemotherapy drugs like oxaliplatin or irinotecan.
- You have at least one tumor that can be measured on a scan.
- Your MSI-H and dMMR test results are negative (not the high-mutation type).
- You are between 18 and 85 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
This trial studies whether giving focused radiation (SBRT) together with fruquintinib and immune drugs (PD-1/CTLA-4) can control advanced, hard-to-remove colorectal cancer. It is for people whose cancer has grown despite standard first- and second-line chemotherapy.
This trial tests if a newer targeted drug (fruquintinib) works as well as a standard drug (bevacizumab) when combined with two chemotherapy drugs for people with advanced colorectal cancer that got worse after first treatment. It aims to find a better option for second-line treatment.
Hear when a new CRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.